2026 Interim Report
Filed with HKEX · Stock code 2487 · · 61 pages · English
Corporate Information 2 Corporate Profile 4 Management Discussion and Analysis 5 Other Information 19 Independent Review Report 37 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 38 Interim Condensed Consolidated Statement of Financial Position 39 Interim Condensed Consolidated Statement of Changes in Equity 41 Interim Condensed Consolidated Statement of C
Earlier from Cutia Therapeutics
- Voluntary announcement - CU-40102 (topical finasteride spray) obtained marketing approval by the macao pharmaceutical administration bureau
- Poll results of the annual general meeting held on 26 June 2026
Later from Cutia Therapeutics
- Change of executive director
- List of directors and their roles and functions
- Voluntary announcement - share repurchase program under the share repurchase mandate
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Next Day Disclosure Return
Follow Cutia Therapeutics into a list and get an email when it puts out news.
Follow Cutia Therapeutics